tiprankstipranks
The Fly

Revelation Biosciences starts Phase 1b clinical study of Gemini in CKD

Revelation Biosciences starts Phase 1b clinical study of Gemini in CKD

Revelation Biosciences (REVB) has started its PRIME – PReconditioning IMmunostimulatory Evaluation – Phase 1b clinical study of escalating doses of intravenously administered Gemini in patients with Stage 3 and 4 Chronic Kidney Disease, or CKD. The US based multi-site placebo-controlled study will enroll up to forty patients in five cohorts of single escalating doses. Top-line data including safety, tolerability, and biomarkers of target activity are expected by mid-year. Data from the PRIME clinical study will support future development in both the GEM-CKD and GEM-AKI programs.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

1